Literature DB >> 12591720

Progesterone receptor expression in neurofibromas.

Margaret E McLaughlin1, Tyler Jacks.   

Abstract

Neurofibromas are benign tumors of the peripheral nerve sheath, which occur sporadically and in association with the common familial cancer syndrome, neurofibromatosis type 1. There are intriguing links between the growth of neurofibromas and levels of circulating hormones: neurofibromas often first appear around the time of puberty, increase in number and size during pregnancy, and shrink after giving birth. We examined 59 human neurofibromas for the expression of estrogen and progesterone receptors (PRs), because their ligands, estrogen and progesterone, were attractive candidate hormones. The majority (75%) of neurofibromas expressed PR, whereas only a minority (5%) of neurofibromas expressed estrogen receptor. Within neurofibromas, PR was expressed by non-neoplastic tumor-associated cells and not by neoplastic Schwann cells. We hypothesize that progesterone may play an important role in neurofibroma growth and suggest that antiprogestins may be useful in the treatment of this tumor.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12591720

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

1.  Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.

Authors:  Lu Q Le; Tracey Shipman; Dennis K Burns; Luis F Parada
Journal:  Cell Stem Cell       Date:  2009-05-08       Impact factor: 24.633

2.  The effect of estradiol, testosterone, and human chorionic gonadotropin on the proliferation of Schwann cells with NF1 +/- or NF1 -/- genotype derived from human cutaneous neurofibromas.

Authors:  Paula Pennanen; Sirkku Peltonen; Roope A Kallionpää; Juha Peltonen
Journal:  Mol Cell Biochem       Date:  2017-11-28       Impact factor: 3.396

Review 3.  Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.

Authors:  Justin Korfhage; David B Lombard
Journal:  Mol Cancer Res       Date:  2019-04-25       Impact factor: 5.852

Review 4.  Spinal manifestations of Neurofibromatosis type 1.

Authors:  Ben Shofty; Ori Barzilai; Morsi Khashan; Zvi Lidar; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-20       Impact factor: 1.475

5.  Tumor segmentation of whole-body magnetic resonance imaging in neurofibromatosis type 1 patients: tumor burden correlates.

Authors:  Michael A Heffler; Lu Q Le; Yin Xi; Avneesh Chhabra
Journal:  Skeletal Radiol       Date:  2016-11-04       Impact factor: 2.199

Review 6.  Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis.

Authors:  Sebastian Laycock-van Spyk; Nick Thomas; David N Cooper; Meena Upadhyaya
Journal:  Hum Genomics       Date:  2011-10       Impact factor: 4.639

7.  Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I.

Authors:  Urania Dagalakis; Maya Lodish; Eva Dombi; Ninet Sinaii; Jessica Sabo; Andrea Baldwin; Seth M Steinberg; Constantine A Stratakis; Brigitte C Widemann
Journal:  J Pediatr       Date:  2013-12-08       Impact factor: 4.406

Review 8.  Gastrointestinal and retroperitoneal manifestations of type 1 neurofibromatosis.

Authors:  Ursula Basile; Giuseppe Cavallaro; Andrea Polistena; Sandra Giustini; Gennaro Orlando; Dario Cotesta; Luigi Petramala; Claudio Letizia; Stefano Calvieri; Giorgio De Toma
Journal:  J Gastrointest Surg       Date:  2010-01       Impact factor: 3.452

9.  Familial adenomatous polyposis: not all masses are desmoids.

Authors:  J Sloane; P Ranchod; G Williams; S K Clark
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

10.  The Nf2 tumor suppressor regulates cell-cell adhesion during tissue fusion.

Authors:  Margaret E McLaughlin; Genevieve M Kruger; Kelly L Slocum; Denise Crowley; Norman A Michaud; Jennifer Huang; Margaret Magendantz; Tyler Jacks
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.